To test whether the genetic modifications performed (namely, the heterologous expression of MeCP2) affected the kinetics of infection or T. gondii’s distribution in the body, we compared total T. gondii levels in the brain and in peripheral tissues (liver, lung and spleen) at 1 and 3 months post injection (mpi). Here, MECP2 is linked to infection.